A new study finds four factors that may make it more likely for some people to experience successful weight loss from using ...

MariTide, a groundbreaking weight loss medication, shows 16% weight reduction in trials. Learn about this promising monthly ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...

Linear relationship seen for waist circumference, BP; reduction in HOMA-IR, hemoglobin A1c seen with modest weight reduction.

Monthly weight-loss shots on the horizon! Learn about new drugs like MariTide and why Black participation in clinical trials ...

Glycemic markers: Hemoglobin A1c decreased across all categories of weight loss and among people who did not lose weight. The average reduction in the group that lost the most weight was 0.65 ...

Efsitora matched or exceeded A1C reductions seen with daily basal insulin across three trials, while orforglipron demonstrated benefits for blood sugar control and weight loss at higher doses.

Results demonstrated a weight loss of up to approximately 20% on average in participants with obesity alone and a weight loss and A1C reduction of up to approximately 17% and 2.2% on average ...

Amgen's weight-loss drug MariTide had a successful Phase 2 trial so the company is expanding development plans to study its use for heart disease and sleep apnea.

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with ...